GT199700043A - Derivados del indazol sustituidos y compuestos relacionados - Google Patents

Derivados del indazol sustituidos y compuestos relacionados

Info

Publication number
GT199700043A
GT199700043A GT199700043A GT199700043A GT199700043A GT 199700043 A GT199700043 A GT 199700043A GT 199700043 A GT199700043 A GT 199700043A GT 199700043 A GT199700043 A GT 199700043A GT 199700043 A GT199700043 A GT 199700043A
Authority
GT
Guatemala
Prior art keywords
tnf
related compounds
production
substituted indazol
derivatives
Prior art date
Application number
GT199700043A
Other languages
English (en)
Inventor
Anthony Marfat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700043A publication Critical patent/GT199700043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA SERIE DE ANALOGOS DEL INDAZOL, NUEVOS QUE SON INHIBIDORES SELECTIVOS DE LA FOSFODIESTERESA (PDE) TIPO IV Y DE LA PRODUCCION DEL FACTOR DE NECROSIS TUMORAL (TNF) Y COMO TALES SON UTILES EN EL TRATAMIENTO DEL ASMA, ARTRITIS, BRONQUITIS, ENFERMEDAD OBSTRUCTIVA CRONICA DE LAS VIAS RESPIRATORIAS, RINITIS ALERGICA, DERMATITIS Y OTRAS ENFERMEDADES INFLAMATORIAS, SIDA, CHOQUE SEPTICO Y OTRAS ENFERMEDADES QUE IMPLICAN LA PRODUCCION DEL TNF. ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA I, EN LA QUE R, R1 Y R2, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT199700043A 1996-05-03 1997-04-10 Derivados del indazol sustituidos y compuestos relacionados GT199700043A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03

Publications (1)

Publication Number Publication Date
GT199700043A true GT199700043A (es) 1998-10-02

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700043A GT199700043A (es) 1996-05-03 1997-04-10 Derivados del indazol sustituidos y compuestos relacionados

Country Status (42)

Country Link
US (2) US6211222B1 (es)
EP (1) EP0912521B1 (es)
JP (1) JP3148254B2 (es)
KR (1) KR100339935B1 (es)
CN (2) CN1112359C (es)
AP (4) AP1147A (es)
AR (1) AR006906A1 (es)
AT (1) ATE292626T1 (es)
AU (1) AU725576B2 (es)
BG (1) BG64211B1 (es)
BR (1) BR9709051A (es)
CA (2) CA2252982C (es)
CO (1) CO4650038A1 (es)
CZ (1) CZ292825B6 (es)
DE (1) DE69732966T2 (es)
DZ (1) DZ2217A1 (es)
EA (1) EA002272B1 (es)
ES (1) ES2238079T3 (es)
GT (1) GT199700043A (es)
HK (1) HK1019443A1 (es)
HN (1) HN1997000046A (es)
HR (1) HRP970227B1 (es)
HU (1) HUP9902459A3 (es)
ID (1) ID16856A (es)
IL (2) IL152083A0 (es)
IS (1) IS4871A (es)
MA (1) MA24158A1 (es)
MY (1) MY132499A (es)
NO (1) NO312959B1 (es)
NZ (1) NZ332240A (es)
OA (1) OA10904A (es)
PE (1) PE64598A1 (es)
PL (1) PL329836A1 (es)
SK (1) SK148298A3 (es)
TN (1) TNSN97070A1 (es)
TR (1) TR199802202T2 (es)
TW (1) TW449585B (es)
UA (1) UA65536C2 (es)
UY (1) UY24532A1 (es)
WO (1) WO1997042174A1 (es)
YU (1) YU16397A (es)
ZA (1) ZA973804B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EP0983249B1 (en) * 1997-05-08 2002-03-13 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
TR200001234T2 (tr) * 1997-11-04 2000-08-21 Pfizer Products Inc. Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
YU25400A (sh) * 1997-11-04 2003-07-07 Pfizer Products Inc. Terapeutski aktivna jedinjenja sa indazolom
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
IL162506A0 (en) 2001-12-14 2005-11-20 Applied Research Systems Ovulation induction
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8277809B2 (en) * 2006-04-21 2012-10-02 Centocor, Inc. CXCL13 antagonists and their use for the treatment of inflammatory diseases
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (es) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU217661B (hu) * 1992-03-09 2000-03-28 Zeneca Ltd. Aril-indazol-származékok, eljárás az előállításukra és herbicidként történő alkalmazásuk
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
WO1996012770A1 (en) * 1994-10-21 1996-05-02 Elisha Technologies Co. L.L.C. Corrosion preventing buffer system for metal products
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
EP0983249B1 (en) * 1997-05-08 2002-03-13 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives

Also Published As

Publication number Publication date
SK148298A3 (en) 2000-02-14
TW449585B (en) 2001-08-11
MA24158A1 (fr) 1997-12-31
AP1146A (en) 2003-02-25
NO985095L (no) 1998-12-29
KR100339935B1 (ko) 2002-07-18
AP1147A (en) 2003-02-25
AP9700975A0 (en) 1997-07-31
CN1217714A (zh) 1999-05-26
CO4650038A1 (es) 1998-09-03
HRP970227B1 (en) 2002-06-30
HUP9902459A3 (en) 2001-10-29
TR199802202T2 (xx) 1999-02-22
IS4871A (is) 1998-10-16
BG102946A (en) 1999-11-30
ATE292626T1 (de) 2005-04-15
PE64598A1 (es) 1998-10-26
HRP970227A2 (en) 2000-12-31
IL126547A (en) 2003-03-12
JP3148254B2 (ja) 2001-03-19
CA2252982A1 (en) 1997-11-13
DZ2217A1 (fr) 2002-12-03
BG64211B1 (bg) 2004-05-31
AP2001002304A0 (en) 2001-12-31
CN1422849A (zh) 2003-06-11
CZ349298A3 (cs) 1999-09-15
ZA973804B (en) 1998-11-02
HK1019443A1 (en) 2000-02-11
WO1997042174A1 (en) 1997-11-13
AR006906A1 (es) 1999-09-29
CN1112359C (zh) 2003-06-25
EA199800882A1 (ru) 1999-06-24
AU1937397A (en) 1997-11-26
ES2238079T3 (es) 2005-08-16
OA10904A (en) 2001-10-11
CA2252982C (en) 2002-10-08
EP0912521A1 (en) 1999-05-06
HUP9902459A2 (hu) 1999-11-29
US6211222B1 (en) 2001-04-03
PL329836A1 (en) 1999-04-12
JPH11508284A (ja) 1999-07-21
US6127398A (en) 2000-10-03
AP2001002294A0 (en) 2001-12-31
NO312959B1 (no) 2002-07-22
DE69732966T2 (de) 2005-09-08
KR20000010751A (ko) 2000-02-25
ID16856A (id) 1997-11-13
NO985095D0 (no) 1998-11-02
CZ292825B6 (cs) 2003-12-17
AU725576B2 (en) 2000-10-12
DE69732966D1 (de) 2005-05-12
EP0912521B1 (en) 2005-04-06
AP0102304A0 (en) 1997-11-03
HN1997000046A (es) 1997-06-26
EA002272B1 (ru) 2002-02-28
IL126547A0 (en) 1999-08-17
BR9709051A (pt) 1999-08-03
IL152083A0 (en) 2003-05-29
TNSN97070A1 (fr) 2005-03-15
YU16397A (sh) 1999-12-27
MY132499A (en) 2007-10-31
NZ332240A (en) 2000-07-28
CA2389918A1 (en) 1997-11-13
UA65536C2 (en) 2004-04-15
UY24532A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
GT199700043A (es) Derivados del indazol sustituidos y compuestos relacionados
GT199700102A (es) Derivados de indazol.
GT199700075A (es) Analogos de indazol sustituido
HN1999000130A (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas.
GT199800058A (es) Derivados de nicotinamida.
DE60210805D1 (de) Substituierte indolizinähnliche verbindungen und ihre verwendung
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
ECSP14013188A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
ECSP067057A (es) Nuevos derivados de piridazin-3(2h)-ona
UY27199A1 (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
DOP2003000638A (es) Tetrahidropiridopiridinicos de la actividad de receptores de quimiocina
AR041252A1 (es) Compuestos de fenil - aza- benzimidazol para modular la ige e inhibir la proliferacion celular, uso en asma, alergia y cancer
CO5280047A1 (es) Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
ES2154683T3 (es) Indoles sustituidos como inhibidores de fosfodiesterasa de tipo iv.
PT672031E (pt) Dieteres de catecol como inibidores selectivos de pde iv
ES2104424T3 (es) Compuestos de isoxazolina como agentes antiinflamatorios.
NO20074961L (no) Imidazopyridazinforbindelser
GT200600297A (es) Nuevos anticuerpos anti-madcam
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
RU2008150621A (ru) Лечение депрессивных расстройств
TW200740808A (en) Inhibiteurs de proteines kinases
ES2172583T3 (es) 5,6-dihidro-9h-pirazol(3,4-c)-1,2,4-triazol(4,3-alfa)piridinas triciclicas.
MX2022016342A (es) Union de anticuerpos multiespecificos a bcma.
CL2009000750A1 (es) Compuestos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona; composicion farmaceutica; y su uso para el tratamiento o profilaxis de trastornos neurodegenerativos, trastornos ateroscleroticos cardio y cerebrovasculares, artritis reumatoide y enfermedades pulmonares como epoc, asma o dolor.
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.